Michael Barbella, Managing Editor09.05.23
MicroVention Inc. has introduced the ERIC Retrieval Device in the United States for ischemic stroke treatment.
Cleared by the U.S. Food and Drug Administration on March 31, 2022, ERIC delivers thrombus control inside and outside of the device, offers no clot integration wait-time to drive procedure efficiency, and offers versatile treatment options for thrombectomy, according to MicroVention.
MicroVention’s ERIC Retrieval Device is a self-expanding laser-cut clot retriever with multiple retrieval cages, located on a pusher wire delivery system. Unlike tubular stents where the ends are open, ERIC is designed to control thrombus through its cage-like design. The product has an atraumatic design that conforms to the natural vessel, offering soft, outward radial force, minimal vessel wall contact, and an exceptionally flexible design. ERIC is offered in three sizes that treat vessel sizes ranging from 5.5 mm to 1.5 mm and is compatible with MicroVention’s HEADWAY 17 and HEADWAY 21 Microcatheters. As part of the initial limited release, the first ERIC cases in the United States were performed at Riverside Methodist in Columbus, Ohio.
ERIC delivers safe and effective outcomes, showing similar results in successful revascularization, clinical and safety outcomes when compared to other retrieval devices, MicroVention claims.
"The ERIC Retrieval Device’s ability to rapidly interact and trap the embolus, coupled with its low-profile design, facilitates synergistic use with SOFIA catheters and reduces time to recanalization," said Dr. Adel Malek, chief of Neurovascular Surgery and director of the Cerebrovascular and Endovascular Division in Tufts Medical Center's Neurosurgery department (Boston). "We are excited to have been the first center in Massachusetts to have clinical experience using the ERIC device and since then have integrated ERIC into our stroke practice."
In addition to the ERIC Retrieval Device, MicroVention’s integrated stroke solution portfolio includes SOFIA Catheters, the BOBBY Balloon Guide Catheter, the WEDGE Microcatheter, HEADWAY Microcatheters, and the TRAXCESS Guidewire.
“The introduction of the ERIC Retrieval Device is guided by our commitment to advancement in stroke innovation. ERIC underscores this commitment to offering physicians and patients vital versatility when every second counts,” MicroVention President/CEO Carsten Schroeder said. “We are thrilled to now offer a fully integrated stroke portfolio that delivers compatibility, versatility, and speed.”
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve cerebrovascular disease treatment. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention, allowing both companies to leverage proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are sold in more than 70 countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, Calif., and San José, Costa Rica.
Terumo is a global leader in medical technology based in Tokyo that employs more than 28,000 associates worldwide and provides solutions in 160-plus countries and regions. The company started as a Japanese thermometer manufacturer and has grown its portfolio to encompass vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, and medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments.
Cleared by the U.S. Food and Drug Administration on March 31, 2022, ERIC delivers thrombus control inside and outside of the device, offers no clot integration wait-time to drive procedure efficiency, and offers versatile treatment options for thrombectomy, according to MicroVention.
MicroVention’s ERIC Retrieval Device is a self-expanding laser-cut clot retriever with multiple retrieval cages, located on a pusher wire delivery system. Unlike tubular stents where the ends are open, ERIC is designed to control thrombus through its cage-like design. The product has an atraumatic design that conforms to the natural vessel, offering soft, outward radial force, minimal vessel wall contact, and an exceptionally flexible design. ERIC is offered in three sizes that treat vessel sizes ranging from 5.5 mm to 1.5 mm and is compatible with MicroVention’s HEADWAY 17 and HEADWAY 21 Microcatheters. As part of the initial limited release, the first ERIC cases in the United States were performed at Riverside Methodist in Columbus, Ohio.
ERIC delivers safe and effective outcomes, showing similar results in successful revascularization, clinical and safety outcomes when compared to other retrieval devices, MicroVention claims.
"The ERIC Retrieval Device’s ability to rapidly interact and trap the embolus, coupled with its low-profile design, facilitates synergistic use with SOFIA catheters and reduces time to recanalization," said Dr. Adel Malek, chief of Neurovascular Surgery and director of the Cerebrovascular and Endovascular Division in Tufts Medical Center's Neurosurgery department (Boston). "We are excited to have been the first center in Massachusetts to have clinical experience using the ERIC device and since then have integrated ERIC into our stroke practice."
In addition to the ERIC Retrieval Device, MicroVention’s integrated stroke solution portfolio includes SOFIA Catheters, the BOBBY Balloon Guide Catheter, the WEDGE Microcatheter, HEADWAY Microcatheters, and the TRAXCESS Guidewire.
“The introduction of the ERIC Retrieval Device is guided by our commitment to advancement in stroke innovation. ERIC underscores this commitment to offering physicians and patients vital versatility when every second counts,” MicroVention President/CEO Carsten Schroeder said. “We are thrilled to now offer a fully integrated stroke portfolio that delivers compatibility, versatility, and speed.”
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve cerebrovascular disease treatment. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention, allowing both companies to leverage proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are sold in more than 70 countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, Calif., and San José, Costa Rica.
Terumo is a global leader in medical technology based in Tokyo that employs more than 28,000 associates worldwide and provides solutions in 160-plus countries and regions. The company started as a Japanese thermometer manufacturer and has grown its portfolio to encompass vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, and medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments.